CHI Advisors LLC - Q3 2020 holdings

$281 Million is the total value of CHI Advisors LLC's 22 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 26.3% .

 Value Shares↓ Weighting
RPTX BuyREPARE THERAPEUTICS INC$77,863,000
+0.3%
2,530,494
+1.1%
27.70%
-8.6%
PLRX BuyPLIANT THERAPEUTICS INC$53,279,000
-28.8%
2,352,291
+2.0%
18.95%
-35.1%
INZY NewINOZYME PHARMA INC$26,529,0001,009,117
+100.0%
9.44%
LRMR  LARIMAR THERAPEUTICS INC$22,985,000
+18.1%
1,515,1480.0%8.18%
+7.6%
KROS SellKEROS THERAPEUTICS INC$21,964,000
+1.0%
569,458
-1.8%
7.81%
-7.9%
FRLN NewFREELINE THERAPEUTICS HLDGSsponsored ads$20,673,0001,324,364
+100.0%
7.35%
AKUS SellAKOUOS INC$19,357,000
-11.8%
846,397
-13.2%
6.89%
-19.6%
ORTX  ORCHARD THERAPEUTICS PLCads$12,047,000
-31.5%
2,931,1850.0%4.29%
-37.5%
AMWL NewAMERICAN WELL CORPcl a$7,361,000248,352
+100.0%
2.62%
DTIL BuyPRECISION BIOSCIENCES INC$6,251,000
-21.8%
1,014,840
+5.7%
2.22%
-28.7%
OVID BuyOVID THERAPEUTICS INC$3,548,000
-11.5%
618,092
+13.6%
1.26%
-19.4%
CRVS BuyCORVUS PHARMACEUTICALS INC$2,339,000
+136.3%
583,232
+60.2%
0.83%
+115.5%
KZR SellKEZAR LIFE SCIENCES INC$1,194,000
-32.4%
246,643
-27.7%
0.42%
-38.3%
GTHX BuyG1 THERAPEUTICS INC$970,000
-9.1%
84,000
+90.9%
0.34%
-17.1%
MYOK SellMYOKARDIA INC$954,000
-26.8%
7,000
-48.1%
0.34%
-33.4%
GBT BuyGLOBAL BLOOD THERAPEUTICS IN$882,000
+7.4%
16,000
+23.1%
0.31%
-1.9%
ADVM BuyADVERUM BIOTECHNOLOGIES INC$721,000
-30.9%
70,000
+40.0%
0.26%
-37.1%
RARE SellULTRAGENYX PHARMACEUTICAL IN$616,000
-39.4%
7,500
-42.3%
0.22%
-44.8%
BPMC SellBLUEPRINT MEDICINES CORP$603,000
-35.6%
6,500
-45.8%
0.22%
-41.1%
LVGO SellLIVONGO HEALTH INC$510,000
-54.8%
3,640
-75.7%
0.18%
-58.9%
BLUE  BLUEBIRD BIO INC$432,000
-11.5%
8,0000.0%0.15%
-18.9%
GBT NewGLOBAL BLOOD THERAPEUTICS INcall$26,00010,000
+100.0%
0.01%
UMRX ExitUNUM THERAPEUTICS INC$0-940,805
-100.0%
-0.17%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-11-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
PRECISION BIOSCIENCES INC17Q3 202313.4%
OVID THERAPEUTICS INC17Q3 20235.8%
CORVUS PHARMACEUTICALS INC16Q2 20231.8%
KEZAR LIFE SCIENCES INC15Q1 20235.8%
PLIANT THERAPEUTICS INC14Q3 202329.2%
REPARE THERAPEUTICS INC14Q3 202330.3%
ORCHARD THERAPEUTICS PLC14Q4 202252.6%
LARIMAR THERAPEUTICS INC14Q3 20239.1%
KEROS THERAPEUTICS INC14Q3 20238.6%
INOZYME PHARMA INC13Q3 20239.4%

View CHI Advisors LLC's complete holdings history.

Latest significant ownerships (13-D/G)
CHI Advisors LLC Q3 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Corvus Pharmaceuticals, Inc.February 13, 20232,384,4025.1%
Cullinan Oncology, Inc.February 13, 20233,317,5447.2%
Freeline Therapeutics Holdings plcFebruary 13, 20234,814,4197.4%
Inozyme Pharma, Inc.February 13, 20232,204,8765.5%
Larimar Therapeutics, Inc.February 13, 20233,473,3668.0%
Oncorus, Inc.February 13, 20232,367,4369.1%
Orchard Therapeutics plcFebruary 13, 20237,987,3966.3%
PLIANT THERAPEUTICS, INC.February 13, 20233,199,8926.6%
Repare Therapeutics Inc.February 13, 20232,800,1266.7%
VectivBio Holding AGFebruary 13, 20235,492,8938.8%

View CHI Advisors LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2023-11-13
13F-HR/A2023-08-22
13F-HR2023-08-11
13F-HR2023-05-11
SC 13G/A2023-02-13
SC 13G/A2023-02-13
SC 13G/A2023-02-13
SC 13G/A2023-02-13
SC 13G/A2023-02-13
SC 13G/A2023-02-13

View CHI Advisors LLC's complete filings history.

Compare quarters

Export CHI Advisors LLC's holdings